See beyond appearances

1 in 3 cancers is a skin cancer

Skin cancer is the most commonly occurring cancer in humans, with an incidence that has steadily increased worldwide. The prognosis of advanced melanoma is poor, and carcinomas are associated with high morbidity.        

60% biopsies result in benign diagnoses

Although dermoscopy is a useful tool for clinical examination, the sensitivity of dermoscopic monitoring is limited by melanomas that may arise in normal skin or in clinically benign nevi that were not initially photographed (link).

20% skin cancers missed at early stage

Dermoscopy improves the diagnostic accuracy for melanoma but only for experienced examiners. Dermoscopy by untrained or less experienced examiners is no better than clinical inspection without dermoscopy (link).

Discover deepLive™

Damae Medical develops deepLive™ medical device, the new best-in-class imaging system pairing penetration and cellular resolution in 3D. deepLive™ is adapted to the imaging of multiple skin conditions, promoting efficient, reassuring and non-invasive patient management.


Based on LC-OCT™ innovative technology

deepLive™ integrates LC-OCT (Line-field Confocal Optical Coherence Tomography) technology which provides a unique 3D imaging modality, allowing the user to   switch from a histology-like vertical mode to a confocal-like horizontal mode,
and to record a 3D stack of tissue volumes in situ. 

  • Image

Navigations in LC-OCT™ 3D stacks


LC-OCT™ imaging of the back of a hand


LC-OCT™ imaging of a fingerprint

User Testimonial

Prof. Mariano Suppa from the Dermatology Department of the Erasme Hospital, ULB Brussels, shares his experience with deepLive™.

  • Image

Quantitative skin analyses
adapted to your studies

  • Image

    Skin Surface 3D segmentation

  • Image

    Dermo-Epidermal Junction 3D segmentation

  • Image

    Keratinocytes distribution

  • Image

    Keratinocytes density with depth

  • Image

    Collagen fibers segmentation

Our company


Company established by Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS (CSO) who filed the patent protecting LC-OCT's technology 


Validation of the potential of LC-OCT 2D imaging for the 2 main types of skin cancer: carcinoma and melanoma


First clinical demonstrator installed at the Saint-Etienne University Hospital


Closing of a €2 million investment round with Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors


First scientific publication: A. Dubois and al., “LC-OCT for high-resolution noninvasive imaging of skin tumors”, JBO 23, 106007


Miniaturized LC-OCT 3D in a handheld probe 
Manufacturing of 10 LC-OCT 3D devices
Launch of clinical validation of LC-OCT 3D


Integration of the live dermoscopic camera inside the LC-OCT 3D handheld probe


Implementation of a scalable production strategy with industrial partners


Damae Medical raises €5M in Series A Financing


deepLive™ receives CE Mark Class IIA under EU MDR 2017/745


deepLive™ installations in over 10 countries in Europe, Japan, Australia and the United States
Publication of the 170th scientific paper on
LC-OCT and its applications


Prof. Arnaud Dubois presents LC-OCT technology


3 key numbers in the development of Damae Medical

Latest News

April 2024
1st Patient Enrolled in Landmark French Health-Economic Study
Read More
March 2023
deepLive™ receives CE Mark Class IIA under EU MDR 2017/745
Read More
February 2022
Damae Medical raises €5M in Series A Financing
Read More

Contact us

Damae Medical
14 rue Sthrau
75013 Paris


If you are looking for a position or an internship, send your CV on this page:
We will get back to you as soon as possible!